ClearLLab 10C reagents panel can be applied to analyze paucicellular samples by flow cytometry.

Autor:	Kajstura M; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA., LaBarge T; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA., Evans AG; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Jazyk:	angličtina
Zdroj:	Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2024 Nov 18. Date of Electronic Publication: 2024 Nov 18.
DOI:	10.1002/cyto.b.22215
Abstrakt:	The FDA-approved ClearLLab 10C Reagents Panel (Beckman Coulter) simplified the diagnosis of leukemias and lymphomas by flow cytometry. However, the requirement of using 3 × 10 6 cells/mL cannot be met for paucicellular samples. Therefore, we tested whether this 10-color panel can be reliably employed to analyze specimens with low cell concentrations. Serial dilutions of 16 samples (5 normal, 11 abnormal), yielding concentrations ranging from 3.0 × 10 6 to 0.0469 × 10 6 cells/mL (64-fold difference), were stained using the B-cell and T-cell panels of the ClearLLab 10C system, and mean fluorescence intensity (MFI) was measured for each antibody. For each cell dilution, the deviation from the value obtained with the FDA-approved concentration of 3.0 × 10 6 cells/mL was calculated. The agreement between the highest and lowest cell concentration data was evaluated by the Bland and Altman method, Pearson's and Spearman's correlation analyses, and linear regression. In all patients, the antigen expression pattern was similar at all cell concentrations tested, and the mean deviation of the MFI from the value obtained using 3.0 × 10 6 cells/mL never exceeded 10% for any of the antibodies. The Bland-Altman method demonstrated the similarity between results obtained with the FDA-approved cell concentration and a 64-fold diluted cell suspension, and a high positive correlation was found between MFI acquired under these two conditions. The tests utilizing the lowest density of cells yielded the same patterns of antigen expression in all patients as those performed with the FDA-approved concentration, documenting a 100% concordance between these two protocols. The ClearLLab 10C panel can reliably determine the expression of markers of leukemias and lymphomas in paucicellular samples containing as little as 0.0469 × 10 6 cells/mL (64-fold lower than the FDA-approved concentration). This finding markedly expands the applicability of the ClearLLab 10C platform in a clinical setting. (© 2024 The Author(s). Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu